Juvenile case of multiple morphea profunda resulting in joint contracture that was successfully treated with cyclosporin A: A case report and review of the published works.
Administration, Oral
Arthritis, Juvenile
/ diagnosis
Biopsy
Child
Contracture
/ diagnosis
Cyclosporine
/ therapeutic use
Dermatologic Agents
/ therapeutic use
Diagnostic Errors
Drug Therapy, Combination
/ methods
Female
Humans
Magnetic Resonance Imaging
Prednisolone
/ therapeutic use
Scleroderma, Localized
/ complications
Skin
/ diagnostic imaging
Treatment Outcome
Wrist Joint
Raynaud's phenomenon
cyclosporin A
joint contracture
methotrexate
morphea profunda
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
17
10
2018
accepted:
14
12
2018
pubmed:
1
2
2019
medline:
10
8
2019
entrez:
1
2
2019
Statut:
ppublish
Résumé
Morphea profunda refers to inflammatory and sclerotic lesions that start primarily from the deep dermis, subcutaneous fat and fascia. Its pediatric case published work is limited. Here, we report the case of an 8-year-old girl with a 5-year history of multiple subcutaneous nodules on her extremities and a right wrist joint contracture who had been previously diagnosed with juvenile idiopathic arthritis and treated with salazosulfapyridine, low-dose prednisolone (PSL) and methotrexate. We performed biopsies of two subcutaneous nodules, which revealed the typical morphology of morphea profunda. She was administrated a tapered course of oral PSL then cyclosporin A (CyA) for 20 weeks which completely resolved her joint contracture and subcutaneous nodules. We reviewed 11 previously reported cases of morphea profunda and found that some include circumscribed/linear morphea that develop into subcutaneous tissues, indicating that "classical" morphea profunda arising within the deep tissues has rarely been reported. Our report is the first to demonstrate the efficacy of CyA for treatment of morphea profunda, and the possibility of CyA as a treatment option to reduce oral steroid doses in juvenile cases.
Identifiants
pubmed: 30701571
doi: 10.1111/1346-8138.14801
doi:
Substances chimiques
Dermatologic Agents
0
Cyclosporine
83HN0GTJ6D
Prednisolone
9PHQ9Y1OLM
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Pagination
354-357Informations de copyright
© 2019 Japanese Dermatological Association.